-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $51

Benzinga·12/02/2025 17:52:27
Listen to the news
Morgan Stanley analyst Patrick Wood maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $56 to $51.